Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$40.25 - $52.99 $241,500 - $317,940
-6,000 Reduced 40.37%
8,863 $368,000
Q1 2023

Apr 28, 2023

SELL
$65.71 - $74.53 $5,716 - $6,484
-87 Reduced 0.58%
14,863 $1.03 Million
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $5,957 - $7,054
87 Added 0.59%
14,950 $1.08 Million
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $5,102 - $6,118
-83 Reduced 0.56%
14,863 $1.09 Million
Q4 2021

Jan 28, 2022

SELL
$53.63 - $62.52 $429 - $500
-8 Reduced 0.05%
14,946 $932,000
Q3 2021

Nov 02, 2021

SELL
$59.17 - $69.31 $2,544 - $2,980
-43 Reduced 0.29%
14,954 $885,000
Q2 2021

Jul 20, 2021

BUY
$61.91 - $67.42 $8,295 - $9,034
134 Added 0.9%
14,997 $1 Million
Q1 2020

May 04, 2020

BUY
$46.4 - $67.43 $281,323 - $408,828
6,063 Added 68.9%
14,863 $828,000
Q1 2020

Apr 27, 2020

SELL
$46.4 - $67.43 $281,323 - $408,828
-6,063 Reduced 40.79%
8,800 $562,000
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $20,696 - $23,343
-375 Reduced 2.46%
14,863 $923,000
Q2 2017

Aug 14, 2017

BUY
N/A
15,238
15,238 $849,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $116B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Saybrook Capital Portfolio

Follow Saybrook Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Saybrook Capital , based on Form 13F filings with the SEC.

News

Stay updated on Saybrook Capital with notifications on news.